JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB224027

FITC Anti-PD-L1 antibody [28-8]

Be the first to review this product! Submit a review

|

(3 Publications)

Rabbit Recombinant Monoclonal PD-L1 antibody - conjugated to FITC. Suitable for Flow Cyt, ICC/IF and reacts with Human samples. Cited in 3 publications.

View Alternative Names

CD274, B7H1, PDCD1L1, PDCD1LG1, PDL1, Programmed cell death 1 ligand 1, PD-L1, PDCD1 ligand 1, Programmed death ligand 1, hPD-L1, B7 homolog 1, B7-H1

2 Images
Flow Cytometry - FITC Anti-PD-L1 antibody [28-8] (AB224027)
  • Flow Cyt

Lab

Flow Cytometry - FITC Anti-PD-L1 antibody [28-8] (AB224027)

Overlay histogram showing CHO-S (blue line) and CHO-PD-L1 transfected (red line) cells stained with ab224027.

The cells were incubated in 1x PBS / 10% normal goat serum to block non-specific protein-protein interactions followed by the antibody (ab224027, 1/500 dilution) for 30 min at 22°C.

Acquisition of >5,000 events were collected using a 20 mW solid-state laser (488nm) and 530/30 bandpass filter.

Immunocytochemistry/ Immunofluorescence - FITC Anti-PD-L1 antibody [28-8] (AB224027)
  • ICC/IF

Lab

Immunocytochemistry/ Immunofluorescence - FITC Anti-PD-L1 antibody [28-8] (AB224027)

ab224027 staining PDL1 in CHO-PDL1 cells. The lower panels demonstrate that ab224027 does not cross react with un-transfected CHO-S cells.

The cells were fixed with 4% formaldehyde (10 min), permeabilized with 0.1% Triton X-100 for 5 minutes and then blocked with 1% BSA/10% normal goat serum/0.3M glycine in 0.1% PBS-Tween for 1h. The cells were then incubated overnight at +4°C with ab224027 at 1/100 dilution (shown in green) and ab195889, Mouse monoclonal to alpha Tubulin (Alexa Fluor® 594), at 1/250 dilution (shown in red). Nuclear DNA was labelled with DAPI (shown in blue).

Image was taken with a confocal microscope (Leica-Microsystems, TCS SP8).

  • 660 APC

    APC Anti-PD-L1 antibody [28-8]

  • 519 Alexa Fluor® 488

    Alexa Fluor® 488 Anti-PD-L1 antibody [28-8]

  • 578 PE

    PE Anti-PD-L1 antibody [28-8]

  • HRP

    HRP Anti-PD-L1 antibody [28-8]

  • 565 Alexa Fluor® 555

    Alexa Fluor® 555 Anti-PD-L1 antibody [28-8]

  • 617 Alexa Fluor® 594

    Alexa Fluor® 594 Anti-PD-L1 antibody [28-8]

  • 603 Alexa Fluor® 568

    Alexa Fluor® 568 Anti-PD-L1 antibody [28-8]

  • 665 Alexa Fluor® 647

    Alexa Fluor® 647 Anti-PD-L1 antibody [28-8] - Extracellular domain

  • Biotin

    Biotin Anti-PD-L1 antibody [28-8] (Detector)

  • Unconjugated

    Anti-PD-L1 antibody [28-8]

  • Carrier free

    Anti-PD-L1 antibody [28-8] - BSA and Azide free (Detector)

  • Carrier free

    Anti-PD-L1 antibody [28-8] - BSA and Azide free

  • Carrier free

    Anti-PD-L1 antibody [28-8] - Low endotoxin, Azide free

Key facts

Host species

Rabbit

Clonality

Monoclonal

Clone number

28-8

Isotype

IgG

Conjugation

FITC

Excitation/Emission

Ex: 495nm, Em: 519nm

Carrier free

No

Reacts with

Human, Human

Applications

Flow Cyt, ICC/IF

applications

Immunogen

The exact immunogen used to generate this antibody is proprietary information.

style
left-column

Alternative Products

Primary Antibodies

AB213480

Anti-PD-L1 antibody [EPR20529]

RabMAb|Recombinant|KO Validated|20ul selling size

Immunocytochemistry/ Immunofluorescence - Anti-PD-L1 antibody [EPR20529] (AB213480)

  • 5
  • 5
Primary Antibodies

AB213524

Anti-PD-L1 antibody [EPR19759]

BOND RX™ Validated|RabMAb|Recombinant|KO Validated|20ul selling size

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PD-L1 antibody [EPR19759] (AB213524)

  • 5
  • 1
Primary Antibodies

AB228415

Anti-PD-L1 antibody [73-10]

BOND RX™ Validated|KO Validated|RabMAb|Recombinant

Immunohistochemistry (Frozen sections) - Anti-PD-L1 antibody [73-10] (AB228415)

  • 5
  • 1
Primary Antibodies

AB274896

Alexa Fluor® 555 Anti-PD-L1 antibody [73-10]

BOND RX™ Validated|RabMAb|Recombinant|Trial Size

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Alexa Fluor® 555 Anti-PD-L1 antibody [73-10] (AB274896)

  • 4
  • 1
Primary Antibodies

AB228462

Anti-PD-L1 antibody [SP142] - C-terminal

BOND RX™ Validated|20ul selling size|RabMAb|Advanced Validation|Recombinant

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PD-L1 antibody [SP142] - C-terminal (AB228462)

  • 5
  • 2

Complementary Products

Assay Kits

AB277712

Human PD-L1 ELISA Kit [28-8]

Recombinant|SimpleStep

ELISA - Human PD-L1 ELISA Kit [28-8] (AB277712)

  • 0
  • 0
Primary Antibodies

AB201825

Alexa Fluor® 647 Anti-PD1 antibody [EPR4877(2)]

RabMAb|Recombinant

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Alexa Fluor® 647 Anti-PD1 antibody [EPR4877(2)] (AB201825)

  • 5
  • 1
Secondary Antibodies

AB150077

Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488)

Immunocytochemistry/ Immunofluorescence - Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) (AB150077)

  • 5
  • 20
Primary Antibodies

AB282114

Alexa Fluor® 594 Anti-CD163 antibody [EPR19518]

RabMAb|Recombinant

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Alexa Fluor® 594 Anti-CD163 antibody [EPR19518] (AB282114)

  • 1
  • 1
Primary Antibodies

AB196147

Alexa Fluor® 647 Anti-CD4 antibody [EPR6855]

RabMAb|Recombinant

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Alexa Fluor® 647 Anti-CD4 antibody [EPR6855] (AB196147)

  • 5
  • 1
style
left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "FlowCyt" : {"fullname" : "Flow Cytometry", "shortname":"Flow Cyt"}, "ICCIF" : {"fullname" : "Immunocytochemistry/ Immunofluorescence", "shortname":"ICC/IF"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "FlowCyt-species-checked": "testedAndGuaranteed", "FlowCyt-species-dilution-info": "1/500", "FlowCyt-species-notes": "<p></p>", "ICCIF-species-checked": "testedAndGuaranteed", "ICCIF-species-dilution-info": "1/100", "ICCIF-species-notes": "<p>This product gave a positive signal in CHO-PDL1 cells fixed with 4% formaldehyde (10 min)</p>" }, "Chinese hamster": { "FlowCyt-species-checked": "notRecommended", "FlowCyt-species-dilution-info": "1/500", "FlowCyt-species-notes": "<p></p>", "ICCIF-species-checked": "notRecommended", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "" } } }
style
left-column

Product details

Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

style
left-column

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Protein A
Storage buffer
Preservative: 0.02% Sodium azide Constituents: PBS, 30% Glycerol (glycerin, glycerine), 1% BSA
Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle|Store in the dark
style
left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

PD-L1 also known as Programmed Death-Ligand 1 or CD274 is a protein involved in immune modulation. Mechanically PD-L1 interacts with its receptors particularly PD-1 to regulate cellular immune responses. This transmembrane protein has a calculated molecular weight of approximately 33 kDa. PD-L1 is expressed on various cell types including tumor cells and immune cells such as dendritic cells macrophages and B cells. Its expression is often upregulated in response to inflammatory cytokines.
Biological function summary

PD-L1 plays a central role in immune evasion mechanisms utilized by tumors. It is not part of a larger protein complex but directly interacts with PD-1 and CD80. When PD-L1 binds to PD-1 it sends inhibitory signals leading to decreased T cell activation and proliferation allowing cancer cells to avoid immune destruction. PD-L1 expression provides a mechanism for tumors to suppress immune surveillance facilitating tumor progression.

Pathways

PD-L1 is integral to the immune checkpoint pathway which is an important regulator of immune response. The interaction between PD-L1 and PD-1 provides a mechanism for immune tolerance which is part of the broader adaptive immune system pathway. PD-L1 is related to other immune checkpoint proteins such as CTLA-4 in its function to limit autoreactivity and promote immune homeostasis.

PD-L1 is most associated with cancer particularly in tumors such as melanoma and non-small cell lung cancer. PD-L1 expression on tumor cells often correlates with poor prognosis. PD-L1 directly interacts with PD-1 in these cancers a target for immunotherapies such as checkpoint inhibitors which aim to block this interaction and restore immune activity against tumors. PD-L1 involvement extends to autoimmune disorders where altered expression can impact tolerance and lead to immune-related tissue damage.
style
left-column
style
left-column

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:
style
left-column

Target data

Plays a critical role in induction and maintenance of immune tolerance to self (PubMed : 11015443, PubMed : 28813410, PubMed : 28813417, PubMed : 31399419). As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response (PubMed : 11015443, PubMed : 28813410, PubMed : 28813417, PubMed : 36727298). Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10) (PubMed : 10581077). Can also act as a transcription coactivator : in response to hypoxia, translocates into the nucleus via its interaction with phosphorylated STAT3 and promotes transcription of GSDMC, leading to pyroptosis (PubMed : 32929201).. The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival (PubMed : 28813410, PubMed : 28813417). The interaction with PDCD1/PD-1 inhibits cytotoxic T lymphocytes (CTLs) effector function (By similarity). The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy (By similarity).
See full target information CD274
style
left-column

Publications (3)

Recent publications for all applications. Explore the full list and refine your search

Oncoimmunology 12:2267744 PubMed37868689

2023

() promoter hypomethylation predicts immunotherapy response in metastatic urothelial carcinoma.

Applications

Unspecified application

Species

Unspecified reactive species

Niklas Klümper,Lennert Wüst,Jonas Saal,Damian J Ralser,Romina Zarbl,Jonas Jarczyk,Johannes Breyer,Danijel Sikic,Bernd Wullich,Christian Bolenz,Florian Roghmann,Michael Hölzel,Manuel Ritter,Sebastian Strieth,Arndt Hartmann,Philipp Erben,Ralph M Wirtz,Jennifer Landsberg,Dimo Dietrich,Markus Eckstein

Viruses 14: PubMed35746739

2022

Intraneuronal β-Amyloid Accumulation: Aging HIV-1 Human and HIV-1 Transgenic Rat Brain.

Applications

Unspecified application

Species

Unspecified reactive species

Hailong Li,Kristen A McLaurin,Charles F Mactutus,Benjamin Likins,Wenfei Huang,Sulie L Chang,Rosemarie M Booze

Journal of cellular physiology 236:1494-1514 PubMed32740942

2020

Hyaluronic acid optimises therapeutic effects of hydrogen peroxide-induced oxidative stress on breast cancer.

Applications

Unspecified application

Species

Unspecified reactive species

Ardeshir Abbasi,Nafiseh Pakravan,Zuhair Mohammad Hassan
View all publications
style
left-column
style
left-column
style
right-column

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com